Abbott’s WGS-based Oncodetect MRD test showed a 30% sensitivity improvement for post-surgical colorectal cancer recurrence.
Hologic has agreed to acquire Reveal Genomics, adding the HER2DX assay to its breast cancer genomic testing portfolio, the ...
Medicare now reimburses Lucid Diagnostics’ EsoGuard esophageal DNA test at $1,938 per test, following its $15 million private ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results